Compare IMKTA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | IMTX |
|---|---|---|
| Founded | 1963 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1994 | N/A |
| Metric | IMKTA | IMTX |
|---|---|---|
| Price | $85.75 | $9.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 110.2K | ★ 325.4K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $5,334,032,609.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.27 | $5.05 |
| 52 Week High | $95.62 | $12.41 |
| Indicator | IMKTA | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 40.53 |
| Support Level | $82.53 | $8.99 |
| Resistance Level | $90.05 | $10.67 |
| Average True Range (ATR) | 2.52 | 0.46 |
| MACD | -0.63 | -0.03 |
| Stochastic Oscillator | 15.00 | 5.04 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.